Diagnostics Industry Leader Jack Kenny Joins Biomerica’s Board of Directors
28 Agosto 2023 - 9:19AM
Biomerica Inc. (NASDAQ: BMRA), a global biomedical company leading
the way in innovative gastroenterology solutions, today announced
the appointment of Jack Kenny, former CEO and board member of
Meridian Bioscience, Inc., to its Board of Directors. Meridian
Biosciences (formerly traded on Nasdaq under VIVO) is a leading
global provider of diagnostic testing solutions. Meridian
Biosciences was acquired on January 31, 2023 by SD Biosensor, Inc.
and SJL Partners LLC in an all-cash transaction valued at
approximately $1.53 billion.
"I'm excited to join Biomerica's Board and contribute to the
launch and growth of the company’s groundbreaking product, inFoods®
IBS. This product holds the potential to not only significantly
improve the lives of millions of individuals dealing with IBS but
also capture the interest of larger multinational diagnostic
companies. The technology's appeal extends beyond its ability to
enhance patient well-being, as it also stands to reduce healthcare
costs and equip physicians with a precise, personalized approach to
treating IBS.
"The compelling clinical study data supporting inFoods IBS has
underscored its potential to deliver therapeutic benefits for IBS
patients. As I take on my role within Biomerica's board, I'm
eagerly looking forward to close collaboration with the management
team. Together, we'll strive to introduce this remarkable
technology to medical professionals and patients around the world
with the goal of improving healthcare outcomes while driving down
costs for patients and insurers," said Mr. Kenny.
“Jack brings a wealth of commercial experience and relationships
in the medical diagnostic industry. His industry insights will be
invaluable as we launch inFoods IBS both domestically and
internationally,” said Zack Irani, CEO of Biomerica. “Jack brings
more than 30 years of experience as a senior executive at large
public companies in the healthcare, clinical laboratory and medical
device industries. Most recently, his leadership as CEO drove
outstanding growth at Meridian Bioscience. Jack also brings strong
public company governance experience that will facilitate corporate
oversite as our business expands and grows.”
Prior to his role as CEO at Meridian, Mr. Kenny was the Senior
Vice President and General Manager, North America at Siemens
Healthcare, and before that was Vice President and General Manager,
U.S. Region for Diagnostic Systems at Becton Dickinson. Throughout
his career, Mr. Kenny has held additional leadership positions of
increasing responsibility including key roles at Leica
Microsystems, Quest Diagnostics and Bayer Diagnostics. He holds a
Bachelor of Science in management systems from Kettering University
in Michigan.
About inFoods IBS:The inFoods IBS test is
designed to assess a patient’s above normal immunoreactivity to
specific foods utilizing a simple finger prick blood sample.
Instead of difficult to manage broad dietary restrictions,
physicians can now use the inFoods IBS information to make
targeted, patient-specific recommendations about specific foods
that, when removed from the diet, may alleviate IBS symptoms such
as pain, bloating, diarrhea and constipation. The inFoods IBS test
and clinical outcomes were studied at several prominent centers
including Mayo Clinic, Beth Israel Deaconess Medical Center Inc. -
a Harvard Medical School Teaching Hospital, Houston Methodist
Hospital, and the University of Michigan. The clinical results for
improvement in the Abdominal Pain Intensity (API) responder
endpoint of >30% reduction in pain, for IBS patients in the
treatment diet arm was greater than patients in the placebo diet
arm (p-value of 0.0246). The improvement for patients in the
treatment arm versus the placebo arm is considered clinically
significant and for certain endpoints is similar and, in some
cases, better than the current drugs in the market. Further
information about Biomerica’s patented inFoods® Technology Platform
can be found at: https://biomerica.com/inFoods/our-technology/. It
is estimated that over 40 million Americans suffer from IBS, with
symptoms often triggered by consumption of specific foods (which
are unique to each patient). The total direct and indirect cost of
IBS has been estimated at $30 billion annually in the United States
alone.
About Biomerica (NASDAQ:
BMRA) Biomerica, Inc.
(www.biomerica.com) is a global biomedical technology company that
develops, patents, manufactures and markets advanced diagnostic and
therapeutic products used at the point of care (in home and in
physicians’ offices) and in hospital/clinical laboratories for
detection and/or treatment of medical conditions and diseases. The
Company’s products are designed to enhance the health and
well-being of people, while reducing total healthcare costs.
Biomerica’s primarily focus is on gastrointestinal and inflammatory
diseases where the Company has multiple diagnostic and therapeutic
products in development.
The Private Securities Litigation Reform Act of 1995 provides a
"safe harbor" for forward-looking statements. Certain information
included in this press release (as well as information included in
oral statements or other written statements made or to be made by
Biomerica) contains statements that are forward-looking, such as
statements relating to the Company’s inFoods® IBS test and other
tests, FDA clearance or possible future clearance of the Company’s
inFoods® IBS test and other products, timing of the commercial
launch of the inFoods® IBS test, the efficacy of the inFoods
product, possible future revenues from the sale of the inFoods® IBS
test, growth in future revenues from the sale of the inFoods® IBS
test, acceptance of the inFoods® IBS test by physicians and their
patients, international regulatory approval and sales of the
inFoods® IBS test, accuracy, efficacy and clinical trial results of
the inFoods® IBS test, the rapidity of testing results,
negotiations with clinical labs who would offer the inFoods® IBS
test, the ability of a CLIA-certified, high-complexity lab to offer
the inFoods® IBS test as a laboratory developed test (LDT),
discussions with physicians and physician groups who could or would
offer the inFoods Test to their patients, efficacy of the inFoods
IBS test to improve IBS symptoms in patients, the company’s ability
to manufacture the inFoods® IBS test as a commercial product and to
increase manufacturing capacity to meet future product demands, any
future FDA marketing authorization, the uniqueness of the Company’s
inFoods® IBS test and other products, pricing of the Company’s
inFoods® IBS test, future possible insurer reimbursement for the
inFoods® IBS test, patent protection on the inFoods® IBS and the
underlying technology of the test, or on any of the Company’s other
products or technologies, and current or future competition for the
inFoods® IBS test from other medical manufacturers or distributors.
Such forward-looking information involves important risks and
uncertainties that could significantly affect anticipated results
in the future, including, without limitation: results of studies
testing the efficacy of the Company’s tests and products;
regulatory approvals necessary prior to commercialization any of
the Company’s products; availability of the Company’s test kits and
other products; capacity, resource and other constraints on our
suppliers; dependence on our third party manufacturers; dependence
on international shipping carriers; governmental import/export
regulations; demand for our various tests and other products;
competition from other similar products and from competitors that
have significantly more financial and other resources available to
them; governmental virus control regulations that make it difficult
or impossible for the company to maintain current operations; the
Company’s ability to comply with current and future regulations in
the countries where our products are made and sold and the
Company’s ability to obtain patent protection on any aspects of its
rapid test technologies. Accordingly, such results may differ
materially from those expressed in any forward-looking statements
made by or on behalf of Biomerica. Additionally, potential risks
and uncertainties include, among others, fluctuations in the
Company's operating results due to its business model and expansion
plans, downturns in international and or national economies, the
Company's ability to raise additional capital, the competitive
environment in which the Company will be competing, and the
Company's dependence on strategic relationships. The Company is
under no obligation to update any forward-looking statements after
the date of this release.
Corporate Contact:
Zack Irani-Cohen949-645-2111 investors@biomerica.com
Source: Biomerica, Inc.
Biomerica (NASDAQ:BMRA)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Biomerica (NASDAQ:BMRA)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024